National drug prices are above the allocatively efficient rate within the US due to poor intellectual property policy on the foreign market and predatory pricing by nationalized healthcare systems outside of the US. This is more of a foreign policy issue than a health policy issue.
Be the first to reply to this answer.
Join in on more popular conversations.
